Companies run numerous disconnected AI pilots in R&D, commercial, and other silos, each with its own metrics. This fragmented approach prevents enterprise-wide impact and disconnects AI investment from C-suite goals like share price or revenue growth. The core problem is strategic, not technical.

Pharma's primary AI challenge is not a lack of experimentation but a failure to execute, scale, and justify ROI. Launching additional pilots only accelerates the activity that keeps companies stuck, compounding the problem instead of solving it.

AI strategies often fail to get sustained funding because they lack detailed financial models beyond simple cost savings. A credible blueprint must quantify projected revenue uplift for each initiative, a step often skipped because strategists lack the deep pharma AI experience to make accurate forecasts.

Most AI ROI models are optimistic projections, not true business cases. They fail because their financial assumptions about user adoption, data availability, and decision speed don't account for the fragmented governance and misaligned incentives that are constraining the organization. The model assumes a reality that doesn't exist.

Many firms engage in "innovation theatre," building a portfolio of impressive but isolated AI pilots. Without a unifying strategic architecture connecting them to core growth objectives, these initiatives remain islands that fail to scale, compound, or move overall enterprise performance.

Many pharma companies allow various departments to run numerous, disconnected AI pilots without a central strategy. This lack of strategic alignment means most pilots fail to move beyond the proof-of-concept stage, with 85% yielding no measurable return on investment.

AI requires significant upfront investment with uncertain returns, creating an "investment paradox" for CFOs. Traditional ROI models are insufficient. A new financial framework is needed that measures not just cost savings but also revenue acceleration, risk mitigation, and the strategic option value of competitive positioning.

A common implementation mistake is the "technology versus business" mentality, often led by IT. Teams purchase a specific AI tool and then search for problems it can solve. This backward approach is fundamentally flawed compared to starting with a business challenge and then selecting the appropriate technology.

A traditional IT investment ROI model misses the true value of AI in pharma. A proper methodology must account for operational efficiencies (e.g., time saved in clinical trials, where each day costs millions) and intangible benefits like improved data quality, competitive advantage, and institutional learning.